UNSPSC 51182047: Tibolone

This classification denotes an anabolic steroid with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FF9X0205V2, chemically known as 19-norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)- but generally known as tibolone, which bears US NIH Compound Identifier 21844. European Medicines Agency schedules Tibolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11022MIG.

UNSPSC 51182047 Tibolone is a Commodity code for a specific pharmaceutical active ingredient, but state and local government procurement under this code actually encompasses generic multi-source pharmaceuticals and over-the-counter (OTC) products distributed through cooperative purchasing agreements. State and local issuing bodies — including state health departments, corrections systems, and participating municipalities within multistate cooperative purchasing alliances — procure these products through framework agreements with manufacturers who supply wholesaler networks. The work involves establishing contracts with pharmaceutical manufacturers that commit to supplying identified products at fixed or competitive pricing structures, with vendors required to maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, supply through designated wholesale distributors with chargeback systems, and provide detailed product data including National Drug Codes, SKUs, UPCs, and packaging configurations. Contracts typically run two years with optional extensions, and manufacturers must carry comprehensive insurance (general liability $5,000,000, network security and privacy liability $2,000,000, professional liability $2,000,000) and accept performance penalties for reporting delays or onboarding failures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic pharmaceuticals and OTC products, with proposals due March 26, 2026. The RFP encompasses participating state and local facilities across Minnesota and Oregon, with awarded vendors to be notified by May 15, 2026 and contracts effective July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with remaining points assigned to fixed pricing structure, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC) and submit pricing in flat price, net price (NF30, NF60, NF90), or WAC-minus formats through the ePro procurement system.